AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

4,424.50GBp
24 Jul 2014
Price Change (% chg)

3.50p (+0.08%)
Prev Close
4,421.00p
Open
4,404.00p
Day's High
4,432.00p
Day's Low
4,370.00p
Volume
1,443,390
Avg. Vol
3,802,457
52-wk High
4,946.41p
52-wk Low
3,085.21p

AZN.L

Chart for AZN.L

About

AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. AstraZeneca discovers, develops and commercializes prescription medicines for six areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation. It has a range of medicines that includes treatments... (more)

Overall

Beta: 0.35
Market Cap (Mil.): £55,887.46
Shares Outstanding (Mil.): 1,262.56
Dividend: 116.80
Yield (%): 3.99

Financials

  AZN.L Industry Sector
P/E (TTM): 46.23 36.00 36.40
EPS (TTM): 0.96 -- --
ROI: 5.15 19.00 18.27
ROE: 9.37 19.78 19.15
Search Stocks

What to Watch in The Day Ahead; Thursday, July 24

(The Day Ahead is an email and PDF publication that includes the day's major stories and events, analyses and other features. To receive The Day Ahead, Eikon users can register at . Thomson One users can register at RT/DAY/US. All times in ET/GMT) Amazon is expected to report a loss of 15 cents per share in the second quarter, sharper than the 2 cents per share loss posted a year ago. The deeper loss partly reflects the e-commerce giant's aggressive expansion into new business segments and reg

23 Jul 2014

European shares bounce back, helped by earnings reports

* Ukraine rebels hand over black boxes from Malaysian plane

22 Jul 2014

European shares bounce back as Ukraine tension ease

* Ukraine rebels hand over black boxes from Malaysian plane

22 Jul 2014

European shares up as Ukraine rebels allow improved access

* Ukraine rebels hand over black boxes from Malaysian plane

22 Jul 2014

European shares rebound as Ukraine rebels hand over black boxes

* Ukraine rebels hand over black boxes from Malaysian plane

22 Jul 2014

AstraZeneca widens cancer immunotherapy net with Advaxis trial

LONDON, July 22 - AstraZeneca is casting its net wider in the hot cancer immunotherapy field through a clinical trial collaboration with U.S. biotech firm Advaxis that will test drugs from both companies in combination.

22 Jul 2014

What to Watch in the Week Ahead and on Monday, July 21

(The Day Ahead is an email and PDF publication that includes the day's major stories and events, analyses and other features. To receive The Day Ahead, Eikon users can register at . Thomson One users can register at RT/DAY/US. All times in ET/GMT) Markets are likely to keep a cautious tone next week, though the downing of a passenger jet over Ukraine and the invasion of Gaza is probably not enough to knock stock markets off their lofty perch. Instead earnings take center stage, with the likes

18 Jul 2014

CORRECTED-UPDATE 1-Shire, AbbVie to announce $53 bln merger by Friday -sources

(Corrects paragraph 7 to show failed bid for AstraZeneca happened in May not June))

17 Jul 2014

CORRECTED-Shire, AbbVie to announce $53 billion merger by Friday -sources

(Corrects 6th paragraph to show Pfizer's failed bid for AstraZeneca happened in May not June)

17 Jul 2014

AbbVie presses case for Shire deal in discreet roadshow

LONDON - AbbVie Chief Executive Richard Gonzalez has pressed the case for his $46 billion pursuit of drugmaker Shire in discreet meetings with shareholders in London this week and is now weighing his next move, according to people familiar with the matter.

03 Jul 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Plunkett Research, Ltd.
$99.00
Provider: ValuEngine, Inc.
$25.00
Provider: S&P Capital IQ – STARS Reports
$127.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks